Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24368019 | 1.00 | IDO1 (0.54) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL21216406 | 0.87 | IDO1 (0.51) | IDO1NOS1AXLMETAP2JAK2 | |
| Hydrochloric Acid SCHEMBL13386757 | 0.84 | IDO1 (0.51) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL2611042 | 0.82 | IDO1 (0.55) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL22079091 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL28592498 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL23021781 | 0.79 | IDO1 (0.60) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL20353958 | 0.79 | IDO1 (0.53) | IDO1NOS1AXLMETAP2JAK2 | |
| SCHEMBL21952718 | 0.78 | TRPA1 (0.40) | IDO1NOS1AXLMETAP2TSHR | |
| SCHEMBL24094124 | 0.78 | NOS1 (0.41) | IDO1NOS1AXLMETAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | IDO1 1847/4885NOS1 1726/4885AXL 860/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | IDO1 4693/4885NOS1 4755/4885AXL 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.